AUTHOR=Sun Chaonan , Chen Ling , Yang Huan , Sun Hongjiang , Xie Zhen , Zhao Bei , Jiang Xuemei , Qin Bi , Shen Zhu 

TITLE=Involvement of Gut Microbiota in the Development of Psoriasis Vulgaris

JOURNAL=Frontiers in Nutrition

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.761978

DOI=10.3389/fnut.2021.761978

ISSN=2296-861X

ABSTRACT=<p><bold>Objectives:</bold> Psoriasis is a common chronic recurrent dermatitis. Accumulating observations show gut microbiota dysbiosis in psoriasis. We intend to further investigate the relationship between intestinal microbiota and psoriasis development.</p><p><bold>Design:</bold> We first performed an epidemiological investigation on differences of gastrointestinal discomfort symptoms between patients with psoriasis and general population. Then variation of gut microbiota in patients with psoriasis (un)treated with acitretin plus narrow-band ultraviolet B (NB-UVB) was analyzed by 16S rRNA sequencing. We last compared recovery status and vital cytokines (lesion and intestine) of mouse psoriasiform models, which were transplanted with fecal microbiota from patients with psoriasis or healthy controls.</p><p><bold>Results:</bold> (1) About 85.5% of patients with psoriasis vs. 58.1% of healthy controls presented with at least one gastrointestinal symptom. The prevalence of investigated symptoms (e.g., abdominal distension and constipation) were significantly higher in patients, compared with controls (<italic>p</italic> &lt; 0.05). Passing flatus and constipation were significantly correlated with psoriasis (<italic>p</italic> &lt; 0.05 in both cases). (2) The abundance of Ruminococcaceae family, <italic>Coprococcus_1</italic> genus, and <italic>Blautia</italic> genus were decreased with psoriasis improvement (<italic>p</italic> &lt; 0.05, respectively), which had been demonstrated significantly increased in psoriasis. (3) Mice receiving psoriatic microbes transplantation showed delayed recovery of psoriasiform dermatitis and less reduction of interleukin (IL)-17A than those receiving healthy microbiota or blank control (<italic>p</italic> &lt; 0.05 and <italic>p</italic> &lt; 0.01, respectively).</p><p><bold>Conclusion:</bold> Multiple evidence we provided here preliminarily demonstrates the involvement of gut microbiota in the different degree of psoriasis activity. The strategy based on overall microbial communities is expected to be a promising supplementary for long-term management of psoriasis.</p>